Furaginum UK Hasco Max 0.1g x 30 tablets


Sale price £13.99 Regular price £20.00

Tax included. Shipping calculated at checkout.
  • The medicinal product Furaginum UK Hasco Max 0.1g contains an increased amount of the active substance, i.e. furazidine. The indication for the use of the preparation are bacterial infections of the lower urinary tract. Can be used from the age of 15.

The active substance is furazidine (Furazidinum). One tablet contains 100 mg of furazidine. The other ingredients are: gelled starch, maize starch, sucrose, colloidal anhydrous silica, stearic acid 50.

The mechanism of action of furazidine contained in the Furaginum UK Hasco Max 0.1g medicinal product consists in inhibiting the growth of bacteria that are responsible for lower urinary tract infections. Furazindine (otherwise known as furagine) is a derivative of nitrofuran. It is recommended to use nitrofuran derivatives during a meal, which contains protein, because it increases its biological availability.

Furaginum UK Hasco Max 0.1g indicated for use in adults and adolescents over 15 years of age in the treatment of acute and recurrent uncomplicated lower urinary tract infections.

Additional information:
Keep the product out of reach of children at room temperature. Avoid drinking alcohol while using furazidine. The drug contains sucrose, it is not recommended for people with rare inherited disorders associated with fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase deficiency.

Do not use in case of hypersensitivity to any component of the drug and derivatives of nitrofuran. Do not use in the first trimester of pregnancy, and in the period of pregnancy (from week 38) and during delivery (this may increase the risk of haemolytic anemia in the newborn). Do not use in children and adolescents under 15 years of age. Do not use in the case of renal failure (creatinine clearance below 60ml / min or elevated serum creatinine). Do not use in the case of recognized polyneuropathy (eg diabetic). Do not use in the case of glucose-6-phosphate dehydrogenase deficiency.

Side effects:
Some people may experience side effects during treatment. Immune system disorders: rarely - anaphylaxis, angioneurotic edema; frequency unknown - pruritus, urticaria, rash. Blood and lymphatic system disorders: frequency unknown - cyanosis due to methemoglobinemia. In people who are deficient in glucose-6-phosphate dehydrogenase, the use of furazidine may lead to megaloblastic or haemolytic anemia. Nervous system disorders: often - headache; frequency unknown - dizziness, drowsiness, visual disturbances, peripheral neuropathy, also with acute or irreversible course (especially renal failure, anemia, diabetes, electrolyte disturbances, vitamin B deficiency). Respiratory, thoracic and mediastinal disorders: frequency unknown - asthmatic reaction in patients with a history of asthma; acute, subacute and chronic hypersensitivity reactions to nitrofuran derivatives. Chronic reactions have occurred in patients receiving nitrofuran derivatives for at least 6 months. Acute respiratory hypersensitivity reactions were manifested by fever, chills, cough, chest pain, dyspnoea, pleural effusion, changes in the radiographs of the lungs and eosinophilia. Most often, they quickly disappeared after discontinuation of the drug. In the case of chronic pulmonary reactions (including pulmonary fibrosis and disseminated interstitial pneumonitis), the severity of symptoms and their reversibility after discontinuation of treatment depends on the time of continuation of treatment after the first side effects. It is important to recognize the side effect as soon as possible and stop taking the medicine. Impaired lung function may be irreversible. Gastrointestinal disorders: often - nausea, excessive gas discharge; frequency unknown - vomiting, constipation, diarrhea, dyspeptic symptoms, abdominal pain, loss of appetite, salivary gland inflammation, pancreatitis, pseudomembranous enteritis. Hepato-biliary disorders: rarely - symptoms of drug-induced hepatitis, cholestatic jaundice, hepatic parenchymal necrosis (usually during long-term use). Skin and subcutaneous tissue disorders: rarely - exfoliative dermatitis, erythema multiforme, Stevens-Johnson syndrome; frequency unknown - alopecia (transient). General disorders and administration site conditions:

Furaginum UK Use as directed by your doctor or as indicated on the leaflet. The Furaginum UK for oral use, it should be taken with a meal that contains protein. Dosage for adults and adolescents over 15 years of age: on the first day, use one tablet 4 times a day, in the next days use one tablet 3 times a day. The treatment lasts 7-10 days. The treatment can be repeated, if necessary after 10-15 days break.